Topline results from the phase IIb ECO-RESET study
FDA approval for Bylvay, the first drug treatment for patients With progressive familial intrahepatic cholestasis.
Japan is the first country to approve casirivimab + imdevimab combination for the treatment of mild to moderate COVID-19.
Bylvay is European Commission approved to treat progressive familial intrahepatic cholestasis.
New Data for Genentech’s Hemlibra reinforce safety profile in people with hemophilia A.
Four-year Biktarvy data presented at IAS 2021
New phase III data support the sustained, long-acting efficacy of lenacapavir
EMA validates MAA for valoctocogene roxaparvovec.
Alexion announces positive results from phase III study of Ultomiris.
bluebird bio announces positive recommendation by EU PRAC committee regarding safety referral review of Zynteglo for transfusion-dependent beta-thalassemia and marketing to resume in EU.bluebird bio announces positive recommendation by EU PRAC committee
Mirikizumab up-regulates genes associated with mucosal healing in ulcerative colitis for up to one year in phase II study.- Eli Lilly.
Tezepelumab regulatory submission accepted and granted FDA priority review for the treatment of patients with asthma. AstraZeneca + Amgen
NMPA accepts sBLA in China for tislelizumab to treat esophageal squamous cell carcinoma- BeiGene Ltd.
Health Canada approves Vyxeos, the first chemotherapy advance in over 40 years for adults with high-risk acute myeloid leukemia .- Jazz Pharmaceuticals
Advaxis Inc, and Biosight Ltd. to merge and trade as Biosight Therapeutics.
Amendment filed to FDA for CCX 168 in vasculitis and PUDFA goal date delayed.- ChemoCentryx
FDA issues complete response for PRV 031 in type 1 diabetes.- Provention Bio
Breakthrough results for Jardiance confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction. Eli Lilly + Boehringer.
FDA approves expanded label for Keytruda for locally advanced cutaneous squamous cell carcinoma that is not curable by surgery or radiation.- Merck Inc.
UK MHRA approval for Byfavo for procedural sedation.- Paion AG.
GSK and Alector announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases.
Positive new data for Johnson & Johnson single-shot COVID-19 vaccine on activity against Delta variant and long-lasting durability of response.
Phase III trial of Covaxin meets primary endpoint in COVID-19 phase III study.- Ocugen/Bharat Biotech
AT 527, an oral antiviral reduces viral replication in hospitalized patients with COVID-19 in phase II interim analysis. Atea + Roche
Seres Therapeutics and Nestle Health Science to jointly commercialise SER 109 ,oral microbiome, in United States and Canada.
Philips announces first patient treated with its new real-time 3D intracardiac echocardiography catheter – VeriSight Pro.
Merck Inc., provides update on Keytruda indication in third-line gastric cancer in the US.
Biosimilars: an option to alleviate the heavy burden of immune-mediated inflammatory diseases
Clinical value beyond price alone: biosimilars improve patient access to treatment
Long-term topical management of psoriasis: the road ahead
Over the horizon: early stage trials for NASH
Phase II trials and stem cell therapies
The next global epidemic
The latest treatments in NASH
The future of organ transplantation
Complications of stem cell transplants
Treating rejection in organ transplants
Challenges in transplant organ rejection
Biologic efficacy for complications associated with moderate-to-severe psoriasis
Moderate-to-severe psoriasis: treatment for young women
Migraine treatments: On the horizon
An independent review of current treatments for migraine
Migraine: The forgotten epidemic?
NEW: Moderate to Severe Asthma Learning Zone launches on Medthority.com